Evidence map›Paper›PMID 36369590›Full record

ArticlePaediatric drugs2023

Adverse Drug Reactions in Children: Comparison of Reports Collected in a Pharmacovigilance Project Versus Spontaneously Collected ADR Reports.

Sarah Leitzen, Diana Dubrall, Irmgard Toni, Julia Stingl, Patrick Christ, Ursula Köberle, Matthias Schmid, Antje Neubert, Bernhardt Sachs

Open access · hybridAbstract read
In one paragraph

Article in Paediatric drugs, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 3 countries.

Sarah Leitzen *Research Division, Federal Institute for Drugs and Medical Devices, Bonn, Germany.ORCID http://orcid.org/0000-0002-1207-4168
Diana Dubrall *Research Division, Federal Institute for Drugs and Medical Devices, Bonn, Germany. Diana.Dubrall@bfarm.de.ORCID http://orcid.org/0000-0002-8763-051X
Irmgard ToniDepartment of Paediatrics and Adolescent Medicine, Universitätsklinikum Erlangen, Erlangen, Germany.ORCID http://orcid.org/0000-0002-0089-1494
Julia StinglInstitute of Clinical Pharmacology, University Hospital of the RWTH Aachen, Aachen, Germany.ORCID http://orcid.org/0000-0002-1566-8156
Patrick ChristResearch Division, Federal Institute for Drugs and Medical Devices, Bonn, Germany.ORCID http://orcid.org/0000-0003-3197-5639
Ursula KöberleDrug Commission of the German Medical Association, Berlin, Germany.ORCID http://orcid.org/0000-0001-8537-202X
Matthias SchmidInstitute for Medical Biometry, Informatics and Epidemiology, University Hospital of Bonn, Bonn, Germany.ORCID http://orcid.org/0000-0002-0788-0317
Antje NeubertDepartment of Paediatrics and Adolescent Medicine, Universitätsklinikum Erlangen, Erlangen, Germany.ORCID http://orcid.org/0000-0001-6575-1452
Bernhardt Sachs *Research Division, Federal Institute for Drugs and Medical Devices, Bonn, Germany.ORCID http://orcid.org/0000-0001-8260-0891
Federal Institute for Drugs and Medical Devices · DEUniversitätsklinikum Erlangen · DEGerman Medical Association · DERWTH Aachen University · DEUniversity Hospital Bonn · DE

Funding

Gemeinsame Bundesausschuss 01NVF16021
6 · The paper itself

Abstract

backgroundAdverse drug reactions (ADRs) and medication errors in children may result from a lack of appropriate drugs, dosages, and pharmaceutical forms. In addition, children may respond differently to drugs than adults. Reporting of ADRs in the pediatric population is therefore of importance in order to increase the amount of safety data. However, different methodological approaches are used to collect ADRs.

objectiveThe aim of the present study was to analyze whether there were differences in the ADRs collected in the KiDSafe project (845 ADR reports) compared with the spontaneous ADR reports sent to EudraVigilance (697 reports) in the same time period. The strengths and limitations of these two different approaches should be discussed.

methodsThe same inclusion criteria were applied for the systematically collected ADRs in the KiDSafe project and the spontaneous reports from EudraVigilance, and only reports of ADRs coded with hospitalization were considered. In both datasets, the number of reports (related to number of hospitals), their documentation quality (VigiGrade), causal relationship (World Health Organization-Uppsala Monitoring Centre [WHO-UMC] criteria), most frequently reported drugs and ADRs, demographical parameters of the patients, reported medical histories, and the seriousness of ADR reports were analyzed descriptively. The results of the two analyses were compared.

resultsThere was considerable underreporting of ADRs via the spontaneous reports (0.4 reports per hospital; 697/1902) compared with 70.4 reports per hospital (845/12) in the systematically collected KiDSafe reports. Documentation quality assessment yielded similar results in both datasets. Among the 10 most frequently reported drugs, anticonvulsants such as levetiracetam (6.6%), valproic acid (5.6%), oxcarbazepine (3.6%), and lamotrigine (3.4%) were mainly reported in the KiDSafe reports, while in the EudraVigilance reports, mite allergen extract (4.4%) and allergens (3.6%) were preferentially reported. Seizures were the most frequently reported clinically specific ADRs in the KiDSafe reports, whereas anaphylactic reactions and urticaria were prominent in the spontaneous reports from EudraVigilance. Notably, the proportion of reports referring to medication errors and other medication safety related issues were more prominent in KiDSafe than in the spontaneous reports (27.8% vs. 12.6% and 46.0% vs. 29.0%, respectively).

conclusionIn general, reports from both data sources contributed to the identification of ADRs and dedicated issues related to drug therapy. However, these differed by nature and strength of the signal, likely due to the characteristics of the individual method. A combined approach could likely compensate for limitations inherent to the single approaches, but will most likely only be applied to dedicated pharmacovigilance topics or research objectives.

Indexed as

Drug-Related Side Effects and Adverse ReactionsPharmacovigilanceAdultAdverse Drug Reaction Reporting SystemsChildHospitalizationHumansMedication Errors

Identifiers

PMID36369590
PMCPMC9931796
OpenAlexW4308835045

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.